Alimera Sciences Inc. (ALIM)’s Financial Results Comparing With Aerie Pharmaceuticals Inc. (NASDAQ:AERI)

Both Alimera Sciences Inc. (NASDAQ:ALIM) and Aerie Pharmaceuticals Inc. (NASDAQ:AERI) are each other’s competitor in the Drug Manufacturers - Major industry. Thus the compare of their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alimera Sciences Inc. 1 0.70 N/A 0.39 1.26
Aerie Pharmaceuticals Inc. 37 21.99 N/A -5.56 0.00

Table 1 demonstrates Alimera Sciences Inc. and Aerie Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Alimera Sciences Inc. 0.00% -72.6% 50.6%
Aerie Pharmaceuticals Inc. 0.00% -108.6% -79.3%

Volatility and Risk

A 2.01 beta means Alimera Sciences Inc.’s volatility is 101.00% more than Standard & Poor’s 500’s volatility. Aerie Pharmaceuticals Inc.’s 63.00% less volatile than Standard & Poor’s 500 which is a result of the 0.37 beta.

Liquidity

Alimera Sciences Inc.’s Current Ratio is 3.3 while its Quick Ratio is 3.1. On the competitive side is, Aerie Pharmaceuticals Inc. which has a 3.5 Current Ratio and a 3.3 Quick Ratio. Aerie Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Alimera Sciences Inc.

Analyst Ratings

In next table is delivered Alimera Sciences Inc. and Aerie Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alimera Sciences Inc. 0 0 2 3.00
Aerie Pharmaceuticals Inc. 0 0 7 3.00

Alimera Sciences Inc. has an average price target of $3.03, and a 507.21% upside potential. Aerie Pharmaceuticals Inc. on the other hand boasts of a $71.44 average price target and a 208.06% potential upside. The information presented earlier suggests that Alimera Sciences Inc. looks more robust than Aerie Pharmaceuticals Inc. as far as analyst opinion.

Insider & Institutional Ownership

Institutional investors held 65.8% of Alimera Sciences Inc. shares and 0% of Aerie Pharmaceuticals Inc. shares. Insiders held 1.5% of Alimera Sciences Inc. shares. Insiders Competitively, held 1.7% of Aerie Pharmaceuticals Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alimera Sciences Inc. -43.35% -45.56% -47.33% -42.35% -55.86% -31.76%
Aerie Pharmaceuticals Inc. -5.66% -22.61% -42.93% -53.76% -67.51% -39.97%

For the past year Alimera Sciences Inc.’s stock price has smaller decline than Aerie Pharmaceuticals Inc.

Summary

Alimera Sciences Inc. beats on 6 of the 9 factors Aerie Pharmaceuticals Inc.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patientÂ’s eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research and development agreement with Royal DSM NV. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.